Search

Avalon GloboCare: A Trifecta Biotech

Summary

  • Avalon GloboCare is an investment gem because it is brewing a highly diversified pipeline of potential blockbusters.

  • Leveraging precision medicine, Avalon employs liquid biopsy with exosomes biomarkers to provide an accurate diagnosis for various cancers and even nonalcoholic steatohepatitis.

  • The crown jewel of the immunotherapy franchise is a premier multi-target CAR-T. It has the power to circumvent prior limitations of the first generation drugs (Yescarta and Kymriah).

  • Remarkably, Avalon is cutting into the gargantuan regenerative medicine market as it harnesses the power of stem cell-derived exosomes.

  • With unique infrastructure and research programs, Avalon is positioned for colossal growth ahead. The financials and valuation indicate highly asymmetric rewards to risks profile.


Source (Full Article): https://seekingalpha.com/article/4271992-avalon-globocare-trifecta-biotech


Piccadilly Chambers
Dudley House
169 Piccadilly
London W1J 9EH

Phone +44 (0) 20 3858 3100

© 2020 by Falcon Capital LLP

Falcon Capital LLP (Registration No. OC320410 ) - Authorised and regulated by the Financial Conduct Authority